

CLINICAL ASSOC PROF KURT A. GEBAUER

DERMATOLOGIST

MBBS, FACD, FACP

QUALIFICATIONS

MBBS University of Western Australia (1986)
Certificate in Sports Medicine RACGP (1986)
Fellow Australasian College of Phlebology (2001)
Clinical Associate Professor University of Western Australia (2008)

ACCREDITATIONS

Fellow of Dermatology Clinical Research in Occupational Dermatology
Fellow of Australasian College of Dermatologists

SUB-SPECIALTIES

CURRENT POSITIONS

PROFESSIONAL EXPERIENCE

Registrar (1989-1990)
Dermatology Royal Derbyshire Infirmary United Kingdom Training position

Registrar Western Australian Rotational Training Program Dermatology (cont)
(1990-1992)

Visiting Medical Officer in Dermatology (1992-1994)
Repatriation General Hospital Hollywood

Locum Consultant Dermatologist (March 1992- June 1992)
Royal Perth Hospital

Consultant Dermatologist (1992-1995)
Fremantle Hospital

Head of Department of Dermatology (1996-2016)
Fremantle Hospital

Visiting Dermatologist (2002-2006)
Albany

BIOGRAPHY

LOCATION

Fremantle

ADDITIONAL INFO

COMMITTEE MEMBERSHIPS

Co-opted Examiner Fellowship Exams September 2000

Australasian College of Dermatologists

Committee for Medical Education January 1996 – January 1999

Australasian College of Dermatologists

Convenor of the Continual Practice

Development Committee January 1999 – January 2006

Australasian College of Dermatologists

Liaison Officer for Dermatology January 1998 – January 2005

University of Western Australia

Examiner in Dermatology

Written papers and Viva Voce prize examination January 1999 – January 2006
University Of Western Australia

Director of Dermatological Training January 1998 - January 2001
University Of Western Australia

Convenor Australasian College of Dermatology Rural Task Force January 2003 –
January 2006

Secretary Australasian College of Dermatology Western Australian Faculty 2008 –
2010

Chairman Australasian College of Dermatology Western Australian Faculty 2010 –
2011

Co-Chair “All About Acne” Australia, Sydney, New South Wales January 2009 -
present

Censor (Examiner) for the Fellowship January 2007 – July 2012
Australasian College of Dermatology

Expert Advisory Committee October 2017 - present
Australasian College of Dermatology

ADDITIONAL INFO

RESEARCH ACTIVITY & CLINICAL TRIALS

1. 2018 – A phase 2 multicenter, investigator-blind, subject-blind, placebo-controlled study of the efficacy, safety, and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativa.
2. 2017 – A randomised, double-blind, vehicle-controlled study of the safety and tolerability of BTX 1204 in patients with mild to moderate atopic dermatitis.
3. 2017 – An open-label study to evaluate the safety and tolerability of BTX 1503 solution in patients with acne vulgaris.

4. 2017 – A phase 3, multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO 1959 (guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis.
5. 2017 – A phase 2a, open-label, proof of concept study to determine the efficacy and safety of etrasimod (APD334) in patients with pyoderma Gangrenosum.
6. 2017 – An open-label study assessing long-term safety of Olumacostat Glasaretil Gel in subjects with acne vulgaris.
7. 2017 – A randomized, double-blind, vehicle-controlled, efficacy and safety study of Olumacostat Glasaretil Gel in subjects with acne vulgaris.
8. 2016 – 2017 A phase 2b randomized, double-blind, placebo-controlled, parallel, multicenter, dose-ranging, study to evaluate the efficacy and safety profile of PF-04965842 in subjects with moderate to severe atopic dermatitis.
9. 2016 – BI 655066 (risankizumab) versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment (IMMhance).
10. 2016 – An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials.
11. 2015 – 2016 A randomized, double-blind, placebo-controlled study of the efficacy and safety of gevokizumab in treating active ulcers of pyoderma Gangrenosum.
12. 2015 – 2016 A phase II, randomized , double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical

corticosteroids.

13. 2015 – 2017 A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab dosing regimens in patients with moderate-to-severe plaque psoriasis.

14. 2015 – 2016 A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.

15. 2015 – 2017 A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.

16. 2015 – 2016 A phase 3b, multicenter, randomized, placebo-controlled, double-blind, double-dummy, study of the efficacy and safety of apremilast (CC-10004), etanercept, and placebo, in subjects with moderate to severe plaque psoriasis.

17. 2014 – 2016 A phase 3, multicenter, randomized, double-blind study to evaluate the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab

18. 2014 – 2015 A phase 2 multi-center, randomized, double-blind, vehicle-controlled, three-arm, parallel group study to assess the safety, tolerability, and efficacy of topical OPA-15406 ointment, in subjects with mild/moderate atopic dermatitis.

19. 2013 – 2016 A phase 3 open-label study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa.

20. 2012 – 2016 A phase 3 study to evaluate the efficacy and safety of

induction and maintenance regimens of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis: AMAGINE-3.

21. 2012 – 2015 A phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa.

22. 2012 – 2013 A multicenter, randomized, double-blind, four-week, bilateral study of the safety and efficacy of two concentrations of AN2728 ointment administered once or twice a day in adolescents with atopic dermatitis.

23. 2012 – A multicenter study with a randomized, double-blind, placebo-controlled induction dosing period followed by a randomized maintenance dosing period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe plaque psoriasis.

24. 2011 A multi-center, randomized, double-blind, vehicle-controlled, bilateral study of the safety and efficacy of AN2898 and AN2728 in the treatment of patients with mild-to-moderate atopic dermatitis.

25. 2011 – 2017 A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis.

26. 2008 – Clinical usage study of LM Naturals stretch mark oil for mothers and for pregnant women.

27. 2005 – 2006 A multi-center, randomized, double-blind, parallel-group, vehicle-controlled study to determine the safety of PEP005 0.0025%, 0.01% and 0.05% gel with two treatment schedules, day 1 & 2 or day 1 & 8 applications to superficial basal cell carcinoma.

28. 2005 – 2006 A multi-center, randomized, double-blind, parallel-group, vehicle-controlled study to determine the safety of PEP005 0.0025%, 0.01% and

0.05% gel with two treatment schedules, day 1 & 2 or day 1 & 8 applications to nodular basal cell carcinoma.

29. 2005 – 2006 A multi-center, randomized, double-blind, parallel-group, vehicle-controlled study to determine the safety of PEP005 0.0025%, 0.01% and 0.05% gel with two treatment schedules, day 1 & 2 or day 1 & 8 applications to actinic keratoses.

30. 2005 – 2006 A phase 1/2 multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety of repeated topical application of three concentrations of NF-kappaB decoy in adults with mild-to-moderate atopic dermatitis.

31. 2005 Topical NF Kappa B Decoy use in adults with atopic dermatitis.

32. 2004 – 2005 Clinical trial measuring uptake of meningococcal vaccine in paediatric patients whilst using topical steroids and topical tacrolimus.

33. 2004 – 2005 A double-blind, multicenter, randomized, parallel group study to demonstrate the equivalence of the response to vaccination of a tacrolimus ointment regimen to a steroid ointment regimen in children with moderate to severe atopic dermatitis.

34. 2004 Trial of Metvix photodynamic therapy for solar keratosis.

35. 2004 Pimecrolimus cream 1% in problematic head and neck dermatitis.

36. 2003 – 2006 Topical copper silicate therapy for Onychomycosis.

37. 2003 Topical therapy (solaraze) for solar keratosis.

38. 2001 – 2007 An open-label study to evaluate the safety and long-term clinical efficacy of imiquimod 5% cream applied once daily 7 days per week for 6

weeks in the treatment of superficial basal cell carcinomas .

39. 2001 – 2006 Topical photodynamic therapy Metvix - in simple and complex basal cell carcinomas.

40. 2000 – 2006 An open multicenter, phase III study of photodynamic therapy with metvix cream 160 mg/g in patients with “high risk” basal cell carcinoma.

41. 1999-2001 Assessing bacterial resistance in acne.

42. 1999 – New formulation topical retinoid acne vulgaris.

1998-2007 Clinical trials of topical therapy in actinic keratoses, superficial and nodular basal cell carcinoma.

43. 1996-1998 Clinical trials of topical therapy – solar keratoses and basal cell carcinoma.